Print

Peptech Limited Successfully Completes Phase I Trial for PN0621  
10/29/2007 8:51:55 AM

29 October 2007 Sydney, Australia: Biopharmaceutical company, Peptech Limited (ASX: PTD, AIM: PTDx) today announced the completion of the Phase I trial of its lead compound for rheumatoid arthritis PN0621.
//-->